A double-blind clinical and ECG-evaluation of lidoflazine (R 7904) in the treatment of stabilized angina pectoris.
D000203:Activities of Daily Living; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D001774:Blood Chemical Analysis; D002986:Clinical Trials as Topic; D004185:Disability Evaluation; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D006321:Heart; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008013:Lidoflazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos; D011299:Prenylamine / Q000008:administration & dosage / Q000627:therapeutic use; D012917:Social Adjustment; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010879:Piperazines; D010919:Placebos; D014665:Vasodilator Agents; D008013:Lidoflazine; D011299:Prenylamine